Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Wakatsuki

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|September 1, 1983
[Ultrasonic diagnosis of multilocular echinococcosis of the liver]T Okai, H Morimoto, K Morioka, et al.
AIDS Research and Human Retroviruses|July 13, 2000
Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cellsA Ryo, Y Suzuki, M Arai, et al.
ESMO Open|August 30, 2021
A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of careK Shimozaki, I Nakayama, D Takahari, et al.
Glia|November 24, 1999
Serial analysis of gene expression in a microglial cell lineH Inoue, M Sawada, A Ryo, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitorK Yoshino, M Tamba, H Osumi, et al.
The American Journal of Cardiology|March 4, 1998
Right and left ventricular wall motion velocities as diagnostic indicators of constrictive pericarditisT Oki, T Tabata, H Yamada, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinomaM Tamba, K Chin, H Osumi, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapyS Udagawa, A Ooki, H Osumi, et al.
ESMO Open|June 22, 2023
Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinomaI Nakayama, D Takahari, K Chin, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal disseminationY Suzuki, K Shimozaki, S Udagawa, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|September 1, 1983
[Ultrasonic diagnosis of multilocular echinococcosis of the liver]T Okai, H Morimoto, K Morioka, et al.
AIDS Research and Human Retroviruses|July 13, 2000
Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cellsA Ryo, Y Suzuki, M Arai, et al.
ESMO Open|August 30, 2021
A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of careK Shimozaki, I Nakayama, D Takahari, et al.
Glia|November 24, 1999
Serial analysis of gene expression in a microglial cell lineH Inoue, M Sawada, A Ryo, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitorK Yoshino, M Tamba, H Osumi, et al.
The American Journal of Cardiology|March 4, 1998
Right and left ventricular wall motion velocities as diagnostic indicators of constrictive pericarditisT Oki, T Tabata, H Yamada, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinomaM Tamba, K Chin, H Osumi, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapyS Udagawa, A Ooki, H Osumi, et al.
ESMO Open|June 22, 2023
Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinomaI Nakayama, D Takahari, K Chin, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal disseminationY Suzuki, K Shimozaki, S Udagawa, et al.
Pageof 15